Keros Therapeutics Inc News - KROS | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (KROS) News

Keros Therapeutics Inc (KROS)

11.84

-0.18

(-1.50%)

Closed January 26 4:00PM

Delayed by 15 minutes

11.76

-0.08

(-0.68%)

After Hours: 6:47PM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 8-K - Current report

Form 8-K - Current report

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec...

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including...

Form 8-K - Current report

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval...

Form 8-K - Current report

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

1
Next

TheFinalCD

TheFinalCD 2 weeks ago

$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

https://x.com/BioStocks/status/1879492237891080688

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
https://x.com/BioStocks/status/1879493199288586404

retireat40

retireat40 1 month ago

Wow. What a turd

retireat40

retireat40 1 month ago

Shocked this is still sub 18

Dennis14

Dennis14 1 month ago

Bought in at 18.00

Monksdream

Monksdream 4 months ago

KROS more upside possible

Monksdream

Monksdream 11 months ago

KROS new 52=week high

Keros Therapeutics

Delayed Upgrade Clock